BioPorto & Ascelia Pharma invite you to an event focusing on Nordic life-science equities.

Invitation to investor event: Market trends in Nordic healthcare equities – featuring presentations by DNB Carnegie, BioPorto Diagnostics A/S & Ascelia Pharma AB

Niels Granholm-Leth, Head of Equity Research DNB Carnegie will open the event with an overview of trends and performance in Nordic healthcare equities.

Julie Waras Brogren, Deputy CEO, presents Ascelia Pharma and, in light of the recently submitted NDA application to the FDA, provides insight into the potential, results, and upcoming milestones for their diagnostics product, Orviglance.

Carsten Buhl, BioPorto’s new CEO, shares his initial reflections after one month in the role and provides insight into the company’s strategy, commercial development, and outlook.

To conclude, a panel will discuss value creation for shareholders – from clinical innovation to commercialization.

To sign up for the event (no later than October 1):  Sign up
Note: the event will be held in Danish

Agenda:

17:00 – Arrival & Refreshments
17:15 – Welcome
17:20 – Nordic healthcare presentation by Carnegie
17:40 – Ascelia Pharma presentation by Julie Waras Brogren
18:05 – BioPorto presentation by Carsten Buhl
18:35 – Panel discussion with Julie Waras Brogren, Carsten Buhl and Niels Granholdm-Leth
19:00 – Closing